Eli Lilly accelerates acquisitions to diversify beyond weight-loss franchise
The drugmaker is buying assets to reduce reliance on its dominant obesity and diabetes portfolio.
The wire
- 01Eli Lilly is ramping up acquisitions to broaden its pipeline beyond weight-loss drugs.
- 02Diversification hedges against pricing pressure and competition in the obesity market.
- 03Specific targets, deal sizes and therapeutic areas were not detailed in the excerpt.
From the source
Read at news.google.comEli Lilly Ramps Up Acquisitions to Diversify Beyond Weight-Loss Drug Dominance